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Shared decision making for advanced heart failure hasbecome both more challenging and more crucial as
duration of disease and treatment options have increased.
High-quality decisions are chosen from medically reasonable
options and are aligned with values, goals, and preferences of
an informed patient. The top 10 things to know about decision
making in advanced heart failure care are listed in Table 1.
Why Shared Decision Making?
Providers have an ethical and legal mandate to involve
patients in medical decisions. Shared decision making recog-
nizes that there are complex trade-offs in the choice of
medical care.1 Shared decision making also addresses the
ethical need to fully inform patients about the risks and
benefits of treatments.2 In the setting of multiple reasonable
options for medical care, shared decision making involves
clinicians working with patients to ensure that patients’
values, goals, and preferences guide informed decisions that
are right for each individual patient.
Grounded in the ethical principle of autonomy,3 judicial
decisions (eg, Cruzan v Missouri Department of Health4) and
legislative actions (eg, the Patient Self-Determination Act5)
have repeatedly affirmed the rights of patients or duly
appointed surrogates to choose their medical therapy from
among reasonable options.6 The formal process of informed
consent before procedural interventions is an embodiment of
this concept in that it underscores the clinician’s obligation to
ensure that the patient has the opportunity to be informed.3 An
informed patient is one who is aware of the diagnosis and
prognosis, the nature of the proposed intervention, the risks
and benefits of that intervention, and all reasonable alternatives
and their associated risks and benefits.7 A major purpose of a
high-functioning healthcare system is to provide the resources
with which an activated, informed patient can engage in prod-
uctive discussions with a proactive, prepared healthcare team.8
Shared decision making moves beyond informed consent.
It asks that clinicians and patients share information with
each other and work toward patient-centered decisions about
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treatment.9 Shared decision making incorporates the perspec-
tive of the patient, who is responsible for articulating goals,
values, and preferences as they relate to his or her health care.
Shared decision making incorporates the perspective of the
clinician, who is responsible for narrowing the diagnostic and
treatment options to those that are medically reasonable.
Shared decision making is most easily applied to preference-
sensitive decisions, in which both clinicians and patients agree
that equipoise exists, and decision support helps patients think
through, forecast, and deliberate their options. However, in
situations in which clinicians hold the view that scientific
evidence for benefit strongly outweighs harm, behavioral sup-
port (eg, smoking cessation counseling) designed to describe,
justify, and recommend specific behavior may also be appropri-
ate and complementary to decision support.10 Finally, certain
therapeutic options may be considered unreasonable and there-
fore independent of patient demands, although situations of
medical futility are relatively rare.6 Although not all patients will
be able to clearly articulate decisions that are congruent with
their stated goals, shared decision making aims to ensure that
patients’ values, goals, and preferences are explored and incor-
porated into the medical decision-making process.
Patient-centered medicine has been suggested as the next
phase in health care.11 Shared decision making puts into practice
the principle of “patient-centered care,” which the Institute of
Medicine has identified as 1 of the 6 pillars of quality,12 with
patient-centered care defined as “providing care that is respectful
of and responsive to individual patient preferences, needs, and
values and ensuring that patient values guide all clinical deci-
sions.”12 The Patient Protection and Affordable Care Act de-
votes 4 pages to patient-centered care, specifically calling for the
development of decision aids, shared decision-making pro-
grams, and metrics for the quality of decision making.13
It will be assumed throughout this document that discussions
and decision making with patients also include, when appropri-
ate, the family and other individuals involved, such as caregivers
and companions. The approach to decision making outlined in
this Scientific Statement takes the perspective of the individual
patient rather than that of society in general. Although individual
medical decisions taken collectively have implications for dis-
tributive justice and resource allocation, it is not the responsibil-
ity of clinicians, patients, or families to directly factor these
global considerations into individual decisions.14 Rather, discus-
sions regarding alternative treatment options, including no treat-
ment, should be focused on meeting a specific individual’s
values, goals, and preferences within the context of societal rules
and regulations.
Why Advanced Heart Failure?
Heart failure affects 2.4% of the adult population and over
11% of the expanding population 80 years old.15 Estimated
total heart failure costs in the United States are projected to
reach 44.6 billion by 2015.15 Existing therapies slow, but
infrequently reverse, disease progression. As a result, the
prevalence of symptomatic heart failure has increased, in-
cluding a prolongation of the advanced phase of the disease.16
The American Heart Association characterizes the far end of
the heart failure continuum as stage D, or “refractory end-
stage heart failure,”17 further defined by others,18,19 including
the European Society of Cardiology (Table 2).20 These
overlapping definitions describe a group of patients for whom
symptoms limit daily life despite usual recommended thera-
pies and for whom lasting remission into less symptomatic
disease is unlikely. The increasing prevalence, high symptom
burden, and possible disease-exchanging therapies (ie, trans-
plantation and mechanical circulatory support) for patients
living with advanced heart failure mandate a systematic and
thoughtful approach to decision making.
This Scientific Statement reviews the clinical context for
decision making in advanced heart failure and provides
Table 1. Top Ten Things to Know
1. Shared decision making is the process through which clinicians and
patients share information with each other and work toward decisions
about treatment chosen from medically reasonable options that are
aligned with the patients’ values, goals, and preferences.
2. For patients with advanced heart failure, shared decision making has
become both more challenging and more crucial as duration of disease
and treatment options have increased.
3. Difficult discussions now will simplify difficult decisions in the future.
4. Ideally, shared decision making is an iterative process that evolves over
time as a patient’s disease and quality of life change.
5. Attention to the clinical trajectory is required to calibrate expectations
and guide timely decisions, but prognostic uncertainty is inevitable and
should be included in discussions with patients and caregivers.
6. An annual heart failure review with patients should include discussion
of current and potential therapies for both anticipated and unanticipated
events.
7. Discussions should include outcomes beyond survival, including major
adverse events, symptom burden, functional limitations, loss of
independence, quality of life, and obligations for caregivers.
8. As the end of life is anticipated, clinicians should take responsibility for
initiating the development of a comprehensive plan for end-of-life care
consistent with patient values, preferences, and goals.
9. Assessing and integrating emotional readiness of the patient and family
is vital to effective communication.
10. Changes in organizational and reimbursement structures are essential
to promote high-quality decision making and delivery of
patient-centered health care.
Table 2. European Society of Cardiology Criteria for
Advanced Chronic Heart Failure
1. Moderate to severe symptoms of dyspnea and/or fatigue at rest or with
minimal exertion (NYHA functional class III or IV)
2. Episodes of fluid retention and/or reduced cardiac output
3. Objective evidence of severe cardiac dysfunction demonstrated by at
least 1 of the following:
Left ventricular ejection fraction 30%
Pseudonormal or restrictive mitral inflow pattern by Doppler
High left and/or right ventricular filling pressures, or
Elevated B-type natriuretic peptide
4. Severe impairment of functional capacity as demonstrated by either
inability to exercise, 6-min walk distance 300 m, or peak oxygen
uptake 12 to 14 mL  g1  min1
5. History of at least 1 hospitalization in the past 6 mo
6. Characteristics should be present despite optimal medical therapy
NYHA indicates New York Heart Association.
Reprinted from Metra et al,20 with permission of the publisher. Copyright ©
2007, Oxford University Press.
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guidance on communication techniques to support these
decisions. Its goal is primarily to help healthcare providers of
all types integrate these concepts into their routine practice to
promote the delivery of effective, safe, efficient, timely,
equitable, and patient-centered care.12 We recognize that
major barriers to the implementation of these concepts are
time, training, and resources. We also recognize the limited
and inequitable access to experts with formal training in heart
failure and palliative care, which leaves many of these
responsibilities to be borne by healthcare providers in a
general medical setting. If the goals of this document are to be
realized, however, the healthcare system will need to make a
fundamental commitment to shared decision making, with
realignment of incentives to support the tailoring of advanced
care to individual patients. Without changes in the structure
of the healthcare team and associated reimbursement, these
recommendations will remain an unfunded mandate that are
unlikely to be fully realized in most practice settings.
Expectations for the Future
● Attention to the clinical trajectory is required to calibrate
expectations and guide timely decisions.
● Predictive models can target high-risk populations but
leave wide uncertainties around estimates of survival for an
individual.
● Difficult discussions now will simplify difficult decisions
in the future.
● Uncertainty is inevitable and should be included in discus-
sions with patients and family.
Estimating Prognosis in Heart Failure
Assessment of prognosis is the foundation for selection
among therapies for life-threatening disease, but this is
particularly challenging for heart failure. The clinical course
varies dramatically across the spectrum of disease severity
and is relatively unpredictable for individual patients (Figure
1).19,21 This contrasts with the more linear decline of patients
with advanced cancer, which has traditionally been the model
for approaches to end-stage disease. Even late in heart failure,
patients often enjoy “good days” and brief interludes of
apparent stability, which can lull them and their care provid-
ers into postponing vital decisions. Prognosis is further
clouded by the unique contrast between unexpected sudden
death (ie, lethal arrhythmia) and lingering death with conges-
tive symptoms (ie, progressive pump failure). Frequent reap-
praisal of the clinical trajectory helps calibrate expectations,
guide communication, and inform rational decisions.
More than 100 variables have been associated with mor-
tality and rehospitalization in heart failure.22–27 Examples of
prognostic factors include demographics (age, sex, race,
insurance status), functional status (New York Heart Associ-
ation functional class and health-related quality-of-life
scores), exercise capacity (peak oxygen consumption,
6-minute walk), cardiac structure and function (cardiac cham-
Figure 1. A depiction of the clinical course of heart failure with associated types and intensities of available therapies. Black line:
Patients tend to follow a progressive, albeit nonlinear, decline in health-related quality of life as the disease progresses; this course can
be interrupted by sudden cardiac death caused by arrhythmia or can end in a more gradual death caused by progressive pump failure.
Gray line: At disease onset, multiple oral therapies are prescribed for cardiac dysfunction and/or treatment of comorbidities. As disease
severity increases, the intensity of care may increase in parallel, with intensification of diuretics, addition of an implantable cardioverter-
defibrillator/cardiac resynchronization therapy for those eligible, and increasing interaction with the medical system through ambulatory
visits and hospitalizations, until the time when standard therapies begin to fail (transition to advanced heart failure). Dotted line: Pallia-
tive therapies to control symptoms, address quality of life, and enhance communication are relevant throughout the course of heart fail-
ure, not just in advanced disease; palliative therapies work hand in hand with traditional therapies designed to prolong survival. The
critical transition into advanced heart failure from the medical perspective is often followed by a transition in goals of care from the
patient and family perspective, wherein palliative therapies may become the dominant treatment paradigm (for the majority of patients
in whom transplantation and mechanical circulatory support are not an option). Clinicians must recognize the transition to advanced
heart failure so that therapeutic options can be considered in a timely fashion and patients are able to proactively match medical deci-
sions to clinical realities. CHF indicates chronic heart failure; MCS, mechanical circulatory support. Modified from Lanken et al;21
reprinted with permission of the American Thoracic Society. Copyright © 2012, American Thoracic Society.
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ber size, ejection fraction), assessments of filling pressures,
biomarkers (natriuretic peptides, inflammatory markers), re-
nal and liver dysfunction, comorbidities (diabetes, lung dis-
ease), clinical events (defibrillator shocks and recent hospi-
talizations), psychosocial factors (depression, social
isolation), and behavioral factors (eg, adherence to the med-
ical regimen).
A variety of multivariable models have been published in
an effort to provide more refined predictions of prognosis in
patients with heart failure (Table 3). The most commonly
used multivariable instruments for estimating prognosis in
symptomatic outpatients are the Heart Failure Survival
Score23 and the Seattle Heart Failure Model.22 In patients
hospitalized for heart failure, a variety of inpatient models
have been developed to predict both in-hospital28 and post-
discharge outcomes.26,27,29–31 These inpatient models have
highlighted the strength of natriuretic peptides, renal func-
tion, and low blood pressure as predictors of survival in
patients in this setting.24 Recently, the first model to predict
both mortality and quality-of-life outcomes after discharge
has been published.32 Although all of these models require
complex mathematical formulas to generate risks, the increas-
ing use of health information technology in the delivery of
care offers the potential to automatically generate risk pro-
files from the electronic medical record.
The application of commonly used ambulatory heart fail-
ure models to the advanced heart failure population can result
in miscalibrated estimates of life expectancy, with significant
underestimation of risk in certain populations.33,34 Therefore,
before recommending general use of risk models, adequate
discrimination (ie, the ability of a model to accurately
distinguish between a patient who will experience the event
versus one who will not)35,36 and calibration (ie, the ability of
the model to accurately predict the observed probability of an
event across levels of risk)37 will need to be validated for
broader populations than those from clinical trials.33,34
Prognosis for Both Quantity and Quality of Life
Most prognostic models in heart failure focus on mortality,
which is easily determined and highly relevant; however,
other clinical outcomes also rank high in importance to
individual patients (Figure 2). Multiple studies have docu-
mented patients’ willingness to sacrifice survival in exchange
for symptom relief, a trade-off that varies between patients
and within the same patient over time and is correlated
loosely with disease severity39,40 but strongly with do-not-
resuscitate status.41 A full discussion of prognosis therefore
includes not only the risks of death but also the potential
burdens of worsening symptoms, limited functional capacity,
loss of independence, reduced social functioning, decreased
quality of life, and increased caregiver commitment.42 Unfor-
tunately, much less is known about the risks of these latter
outcomes. The only existing model that estimates the risk of
unfavorable future quality of life shows important differences
from risk models for death, particularly the relative impor-
Table 3. Selected Prognostic Models in Heart Failure
Key Covariates Outcome
Ambulatory
Heart Failure Survival Score23 Peak V˙O2, LVEF, serum sodium, mean BP, HR, ischemic etiology, QRS
duration/morphology
All-cause mortality
Seattle Heart Failure Model22
(depts.washington.edu/
shfm)22a
NYHA function class, ischemic etiology, diuretic dose, LVEF, SBP, sodium,
hemoglobin, percent lymphocytes, uric acid, and cholesterol
All-cause mortality, urgent transplantation,
or LVAD implantation
Hospitalized
EVEREST Risk Model22 Age, diabetes, h/o stroke, h/o arrhythmia, -blocker use, BUN, sodium,
BNP, KCCQ scores
The combined end point of mortality or
persistently poor quality of life (KCCQ
45) over the 6 mo after discharge
EFFECT29 Age, SBP, respiratory rate, sodium, hemoglobin, BUN, h/o CVA, h/o
dementia, h/o COPD, h/o cirrhosis, h/o cancer
30-d and 1-y mortality
ADHERE28 BUN, SBP, serum creatinine In-hospital mortality
ESCAPE Discharge Score31 BNP, cardiopulmonary resuscitation or mechanical ventilation during
hospitalization, BUN, sodium, age 70 y, daily loop diuretic dose, lack of
-blocker, 6-min walk distance
6-mo mortality
V˙O2 indicates oxygen consumption; LVEF, left ventricular ejection fraction; BP, blood pressure; HR, heart rate; NYHA, New York Heart Association; SBP, systolic BP;
LVAD, left ventricular assist device; EVEREST, Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan; h/o, medical history of; BUN, blood
urea nitrogen; BNP, B-type natriuretic peptide; KCCQ, Kansas City Cardiomyopathy Questionnaire; EFFECT, Enhanced Feedback for Effective Cardiac Treatment; CVA,
cerebrovascular accident; COPD, chronic obstructive pulmonary disease; ADHERE, Registry for Acute Decompensated Heart Failure Patients; and ESCAPE, Evaluation
Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness.
Figure 2. Prognosis is not only about expectations for survival.
There are multiple domains that are of varying importance to
individual patients. Adapted from Spilker.38
Allen et al Decision Making in Advanced Heart Failure 1931
tance of current measures of quality of life.32 More astute
anticipation of an unfavorable quality of life until death, in
addition to anticipation of death, would better identify pa-
tients for whom detailed discussions of prognosis and options
are appropriate. In choosing among options, this information
gap regarding nonmortality patient-centered outcomes is
exacerbated by the lack of rigor in collecting health status
information in major trials, although this is improving. Even
less is known about the relative impact of the disease and
therapies on caregiver burden and quality of life for family
members.43–46
Uncertainty for the Individual
Even under these idealized circumstances, most models
designed to predict mortality have only modest accuracy.47
Further complicating practical use, prediction models repre-
sent the average survival for a population of patients with
characteristics similar to those of the individual patient. A
70% chance of 2-year survival does not directly translate to
an individual who will instead be 100% alive or dead at any
point in time. For patients with advanced disease, interest
often focuses instead on the expected length of time remain-
ing; patients ask the question, “How long do I have?” This
point prediction of survival time48 is even more difficult to
estimate.49,50 Even if a model fits well for a cohort and the
estimated survival curve provides a good fit to the data, it is
not clear where along the curve an individual patient will lie.
As an example of the difficulty in estimating survival
duration, one can consider the median survival estimate (50%
survival at time x) as an estimation of the time in which half
of the patients will live longer and half will live for a shorter
time. Parkes51 defines an “error” in survival as an estimate
more than twice as long as the actual survival or less than half
the actual survival. That is, if a patient survived for 12
months, a predicted survival of 2 years or 6 months
would be considered an error by this definition. This error
depends on the variability in survival times for patients, more
specifically on the standard deviation of the logarithm of
survival time. Using several statistical models of survival, the
probability of greater than 2-fold error remains near 50%
under realistic assumptions.49
Ultimately, the stochastic nature of heart failure conveys a
high level of prognostic uncertainty for most patients. Future
events have a certain degree of unpredictability, such that
improved understanding of risk tends to add incrementally
less prognostic information to existing models. Even a perfect
model that includes all possible measurements describes only
what has already happened. The trajectory can often be
steepened by new conditions or life events, such as myocar-
dial infarction, a serious fall, or the death of a spouse. It is
vital to acknowledge uncertainty in discussions about future
care.
Need for Accurate Estimates of Risk
Despite limitations of prognostic models, they are generally
more accurate than clinical intuition, which is prone to bias.
A review of survival predictions among terminally ill cancer
patients52 found that physicians consistently overestimated
survival, which has been seen in other studies.51,53 For
patients discharged from the hospital with advanced-stage
heart failure, both physicians’ and nurses’ survival estimates
had modest ability to discriminate those who subsequently
died from those who lived (with nurses outperforming phy-
sicians), but absolute estimates were significantly miscali-
brated, again overestimating survival.54 In patients with
chronic heart failure, the patient-predicted survival also
tended to overestimate survival versus model-based predic-
tions, particularly for younger patients.55 Clinicians need to
learn how to leverage objective risk models, while recogniz-
ing their limitations and adapting them on the basis of their
unique clinical and psychosocial features and serial assess-
ments not generally incorporated into such models.
Anticipation, Timing, and Review
● An annual heart failure review with patients should
include discussion of current and potential therapies for
both anticipated and unanticipated events.
● On the day of hospital admission, it is far better to review
rather than introduce advanced care decisions, which re-
quires that patient preferences have been discussed previ-
ously and documented in the ambulatory setting.
● Clinical milestones such as implantable cardioverter-
defibrillator (ICD) shocks or recurrent hospitalization
should trigger interim review and discussion of treatment
options and preferences.
Timing of Discussions
Finding appropriate time to discuss preferences, prognosis,
and medical options is a formidable challenge. Such discus-
sions require a major commitment of time, focus, and
emotional energy, which is not in synchrony with the frenetic
pace and frequent interruptions of clinical practice. Current
organizational and reimbursement structures provide strong
disincentive to such intense encounters.
As a result, formal discussions about prognosis and deci-
sion making are often deferred until more emergent and less
favorable occasions, when thoughtful decision making may
be impaired. For instance, at the time of presentation for
hospital admission with decompensated heart failure, patients
are frequently uncomfortable and often require urgent, inten-
sive evaluation and management. Clinicians responsible for
delivering care in this setting are typically unfamiliar with the
patient and overall disease trajectory. Hasty questions such
as, “Do you want us to do everything?” and “Would you want
to be kept alive as a vegetable?” can yield inaccurate and
conflicting answers. It has been shown that patients deciding
resuscitation preferences during an acute hospitalization fre-
quently reverse their decisions over the next few months.56
Therefore, optimal shared decision making requires that
patient preferences have been discussed previously and doc-
umented in the ambulatory setting. The day of hospital
admission is a time to review and possibly update, rather than
introduce, advanced care decisions. On the other hand, once
the clinical course has become apparent during hospitaliza-
tion, clinicians can take advantage of the substantial time they
have with the patient and family to further address complex
medical decisions before discharge. When the expected
survival or quality of life is very limited, hospitalization may
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also afford better access to multidisciplinary teams, palliative
care, and other resources than can be marshaled in the
outpatient setting. All of these considerations underscore the
importance of a proactive, anticipatory, and iterative ap-
proach to soliciting patients’ preferences. This should occur
both routinely and at the occurrence of milestones that herald
a worsening prognosis (Table 4).
Annual Heart Failure Review
The “Annual Heart Failure Review” is a concept based on the
annual wellness visits that have long been a successful part of
primary care. This reflects the principle and practice of
“anticipatory guidance,” the psychological preparation of a
person to help relieve the fear and anxiety of an event
expected to be stressful. When triggered by a scheduled
anniversary in the same way as well baby visits or periodic
mammography, an automatic annual review can open a broad
dialogue with patients and families without the unvoiced
concern that it signifies bad news. In heart failure, this may
coincide, for example, with an annual influenza vaccination
or at 1-year increments roughly originating from the date of
diagnosis. It may be convenient to have this review occur in
temporal proximity to an annual general medical evaluation,
particularly with regard to screening studies, for which the
indications might change in the setting of progressive heart
disease.
In the annual review visit (Table 5), a variety of tasks could
be accomplished. Patients could summarize their recent
symptom burden and quality of life. Goals for the coming
year and preferences for outcomes including survival, func-
tional capacity, and quality of life could be solicited. A range
of prognosis would be estimated and broadly conveyed.
Current treatment with drugs and devices could be reviewed
relative to indicated treatment based on the patient’s heart
failure type, stage, and trajectory. Similarly, evaluation and
management of new relevant comorbidities could be re-
viewed, such as sleep apnea, anemia, and depression. “Vol-
untary advance care planning,” including formal designation
of a healthcare proxy and do-not-resuscitate status, which has
been proposed as part of the initial Medicare visit and
subsequent “wellness visits,”60(p73406) would be essential and
would take place naturally within the context of an annual
review.
This scheduled review would require considerable face-to-
face time between the patient, family, and physician. The
results of this discussion should be documented specifically
in a designated area of the chart available to all who might be
involved in the patient’s current and future care.
Responding to Milestones
Although heart failure is a chronic disease, its clinical course
often includes sudden changes. There are several “mile-
stones” in the clinical course of heart failure that can
represent an “inflection point” in the overall trajectory (Fig-
ure 119,21), such as first ICD shock, rehospitalization, devel-
opment of cardiorenal syndrome, withdrawal of angiotensin-
converting enzyme inhibitors, or intubation. Once the acute
condition has been addressed, such events should trigger a
focused version of the “Heart Failure Review,” which would
include reassessment of prognosis, treatment options, and
patient preferences.
Table 4. Triggers for Formally Assessing Prognosis and
Having Conversations About Goals of Care and Voluntary
Advance Care Planning
Routine
“Annual Heart Failure Review” with a scheduled clinic visit
Event-driven “milestones” that should prompt reassessment
Increased symptom burden and/or decreased quality of life
Significant decrease in functional capacity
Loss of ADLs
Falls
Transition in living situation (independent to assisted or LTC)
Worsening heart failure prompting hospitalization, particularly if
recurrent57
Serial increases of maintenance diuretic dose
Symptomatic hypotension, azotemia, or refractory fluid retention
necessitating neurohormonal medication underdosing or withdrawal58
Circulatory-renal limitations to ACEI/ARB
Decrease or discontinuation of -blockers because of hypotension
First or recurrent ICD shock for VT/VF59
Initiation of intravenous inotropic support
Consideration of renal replacement therapy
Other important comorbidities: new cancer, etc
Major “life events”: death of a spouse
ADL indicates activities of daily living; LTC, long-term care; ACEI, angioten-
sin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; ICD,
implantable cardioverter-defibrillator; VT, ventricular tachycardia; and VF,
ventricular fibrillation.
Table 5. Selected Components That May Be Included in an
Annual Heart Failure Review
Characterization of clinical status
Functional ability, symptom burden, mental status, quality of life, and
disease trajectory
Perceptions from caregiver
Solicitation of patient values, goals, and general care preferences
Estimation of prognosis
Consider incorporating objective modeling data
Orient to wide range of uncertainty
Review of therapies
Indicated heart failure therapies in appropriate patients (BB, ACEI/ARB, AA,
CRT, ICD)
Treatment of comorbidities (AF, HTN, DM, CKD, etc)
Appropriate preventive care, within the context of symptomatic heart
failure
Planning for future events/advance care planning
Resuscitation preferences
Desire for advanced therapies, major surgery, hospice
Standardized documentation of the annual review in the medical record
BB indicates -blocker; ACEI, angiotensin-converting enzyme inhibitor; ARB,
angiotensin II receptor blocker; AA, aldosterone antagonist; CRT, cardiac
resynchronization therapy; ICD, implantable cardioverter-defibrillator; AF, atrial
fibrillation; HTN, hypertension; DM, diabetes mellitus; and CKD, chronic kidney
disease.
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Framework of Options
● Physicians are responsible for defining the range of options
that are medically appropriate.
● Presentation of major interventions should always include
specific description of alternative approaches, including
continuation or withdrawal of ongoing treatments and
focus on symptomatic care.
● Discussions should include a range of anticipated out-
comes, including not only survival but also major adverse
events, independence, functional capacity, and quality of
life for both patient and caregiver, even if to acknowledge
lack of this information for some interventions.
● Therapies that may lead to dependence should be weighed
carefully before initiation even when anticipated to be
temporary (eg, intravenous inotropes, renal replacement
therapy, and intubation).
● Benefits and risks of noncardiac procedures should be
reviewed in the context of competing risks for death and
functional limitation attributable to heart failure (eg, hip
replacement, repair of asymptomatic aortic aneurysm, or
screening tests).
● Decisions for major cardiac and noncardiac interventions
should include consideration of “what if” situations of
unanticipated adversity.
● Referral to a palliative care team should be considered for
assistance with difficult decision making, symptom man-
agement in advanced disease, and caregiver support even
as patients continue to receive disease-modifying therapies.
In the face of the increasing complexity of diagnostic and
treatment options for heart failure, a framework for classify-
ing various medical decision-making scenarios should help
clinicians better anticipate those decisions most likely to
occur as the disease progresses to an advanced stage (Table
6). Too frequently, the default assumption is that patients
would “want everything done.” Rather, it is the clinicians
who are responsible for defining the “everything” set of
interventions that are medically reasonable. From these,
patients and families can choose those most consistent
with their values, preferences, and goals. It is increasingly
explicit in quality metrics that those groups or institutions
offering specific advanced therapies should include palli-
ative care and access to ongoing care regardless of the
therapies chosen.
Continuation of Stage C Medical Therapies
While anticipating and addressing new options that accom-
pany the transition to advanced stage D heart failure, medical
therapy usually includes all stage C therapies.17,61,62 The
Table 6. Framework of Major Medical Decisions in Advanced Heart Failure Faced by Patients and Their Clinicians
Types of Options Specific Examples of Interventions
Generally Considered Only
for HF With Reduced
LVEF
Examples of Uncommon Outcomes That Could Be
Anticipated With “What If” Discussions in
High-Risk Patients
Major interventions that may
improve cardiac function
CABG
Valve surgery
Pericardial stripping
Percutaneous valve intervention
Worsened cardiac function/inability to come off
bypass or IABP: Place MCS?
Ventilator dependence: Extubate? When?
Stroke: Feeding tube? Institutional care?
PCI Coronary occlusion: Revert to CABG?
CRT X Unable to place coronary sinus lead: Convert to
thoracotomy?
Therapies that only reduce the
risk of sudden cardiac death
ICD X Terminal or permanently disabling disease:
Device deactivation?
Adjunctive therapies instituted
during acute decompensation
with potential chronic
dependence
Temporary support devices (IABP,
percutaneous VAD, ECMO)
X Unable to wean: Convert to permanent MCS or
withdraw?
IV inotropes X Unable to wean: Transition to home inotropes or
discontinue?
Renal replacement therapy (dialysis or
ultrafiltration)
Failure of acute injury to resolve: Initiate
indefinite hemodialysis or discontinue?
Advanced surgical therapies to
exchange disease
Transplantation X Early graft failure or other serious postoperative
complications: MCS or withdraw support?
Later graft failure: Retransplantation?
Permanent MCS/LVAD X Stroke, infection, or recurrent bleeding: Turn off
device?
Noncardiac procedures for
comorbidities
Joint replacement
Hernia repair
Worsening heart failure causing hemodynamic
and/or respiratory collapse: Continue ventilatory
support and/or initiate circulatory support?
Resection of pulmonary nodule
Asymptomatic aortic aneurysm repair
Screening colonoscopy
Not generally to be done,
because risks are thought
to outweigh potential
benefit
HF indicates heart failure; LVEF, left ventricular ejection fraction; CABG, coronary artery bypass grafting surgery; IABP, intra-aortic balloon pump; MCS, mechanical
circulatory support; PCI, percutaneous coronary intervention; CRT, cardiac resynchronization therapy; ICD, implantable cardioverter-defibrillator; VAD, ventricular assist
device; ECMO, extracorporeal membranous oxygenation; and IV, intravenous.
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initial approach to stage D heart failure is optimization of
these treatments. The need to decrease or discontinue neuro-
hormonal antagonists is a milestone, as described in Table 4.
Major Interventions That Might Improve Cardiac
Function and Clinical Outcomes
High-Risk Cardiac Surgery
Patients may be considered for cardiac surgery for coronary,
valvular, and pericardial disease. These surgeries are partic-
ularly high risk as a consequence of the patient’s advanced
heart failure. These procedures may be pursued either with
the hope of improving the heart failure condition or in
response to a superimposed diagnosis such as angina or
acquired aortic stenosis. It is usually anticipated that there
will be substantial residual cardiac dysfunction even if the
surgery is successful. Although the intent may be to improve
cardiac function, the benefit of cardiac surgery in most
patients with advanced chronic heart failure is not estab-
lished. Even if the cardiac function improves, the surgery and
related events may lead to prolonged morbidity and possibly
death.63 The potential for protracted postoperative rehabilita-
tion and loss of independence must be considered and
included thoughtfully in the shared decision, because surgery
inherently increases short-term risk for the prospect of
longer-term benefit. Unfortunately, there is limited informa-
tion about the frequency of these outcomes beyond general
estimates of prolonged hospitalization in the Society of
Thoracic Surgery risk scores.64
Percutaneous Interventions
Less invasive percutaneous approaches for the treatment of
coronary and valvular disease may be appealing in advanced
heart failure because of the increased surgical risk among
these patients. However, potential benefits depend on a
variety of factors and are relatively unknown for the ad-
vanced heart failure population; meanwhile, risks of contrast-
induced nephropathy65 and 30-day mortality66 are markedly
increased in this population. Percutaneous approaches to
valvular disease are less well developed than for coronary
disease, but the technology is improving rapidly. Catheter
approaches to both aortic67 and mitral68 disease have now
been shown to be reasonable alternatives to surgery in certain
populations. The benefits of valve repair or replacement are
less well established in patients with significant heart failure,
especially when treating functional (secondary) mitral regur-
gitation for patients with a dilated left ventricle.69 The acute
risk of stroke must be weighed against potential longer-term
benefits. Decisions regarding percutaneous interventions
should also include consideration of whether emergency “bail
out” surgery would be appropriate and feasible.
Pacing Device Therapy
Cardiac resynchronization therapy (CRT) represents a clini-
cal challenge in advanced heart failure. Patients with New
York Heart Association functional class IV heart failure have
represented a small fraction of patients included in random-
ized trials of CRT.70 Although there are some reports sug-
gesting that CRT can improve outcomes for patients taking
intravenous inotropes, these findings have not been consis-
tent, and the reports have methodological limitations.71,72
Before left ventricular lead implantation or ICD device
upgrade, the care team should plan for contingencies. For
instance, if the lead cannot be placed transvenously, will there
be consideration of an open thoracotomy for placement, with
the attendant morbidity of a chest tube and possible recurrent
pleural effusion in the setting of chronically elevated right
atrial pressures? The risk-benefit ratios of the full comple-
ment of possible procedural variations, in the context of
patient preferences, should be considered before any proce-
dure so that the patient can provide truly informed consent
and a response to potential adverse outcomes is planned
a priori. Factors likely to modify the risk-benefit ratio of
device implantation, such as noncardiovascular morbidity and
acute decompensation, should also be recognized and incor-
porated into these discussions.73,74
Although CRT pacers and ICDs can be packaged together,
their purposes are quite different. CRT, like neurohormonal
antagonist therapy, is designed to reverse remodeling and
improve cardiac performance. Although CRT has been shown
to improve survival, it also can have significant effects on
symptom reduction and quality of life in select patients. In
contrast, ICDs treat life-threatening arrhythmia without im-
proving symptoms. Patients may not understand the distinc-
tion until after the device has discharged or the issue of
deactivation is raised. Recommendation for a combined
CRT-defibrillator (CRT-D) device should prompt separate
discussions on the indications for defibrillator capacity versus
cardiac resynchronization, as well as differences in need for
monitoring, chances for inappropriate shocks and worsening
heart failure, risks for infection and lead malfunction, and
options for deactivation.
ICDs to Reduce the Risk of Sudden Cardiac Death
ICDs are fundamentally different than many life-saving
therapies for patients with chronic heart failure with reduced
ejection fraction. Neurohormonal antagonist medications and
CRT improve cardiac function, thereby reducing mortality,
reducing hospitalization, and improving quality of life. In
contrast, ICDs improve survival by aborting lethal arrhyth-
mias but do not improve cardiac function or heart failure
symptoms. Additionally, ICDs can create an additional bur-
den for patients, particularly from inappropriate discharges
and prevention of a rapid death. Because ICDs involve this
trade-off between reduced risk of sudden cardiac death and an
increased risk of hospitalization,75 potential decrease in qual-
ity of life,76 and higher likelihood of prolonged death from
progressive pump failure, meticulous discussion of absolute
risks with and without ICDs are particularly important for
informed consent and shared decision making.
Temporary Therapies With Potential Dependence
Some therapies are intended for short-term use to stabilize
patients, thereby allowing for recovery from reversible insults
or transition to more definitive therapy (ie, cardiac transplan-
tation or permanent mechanical circulatory support). Al-
though initially intended as a temporary intervention, such
stabilizing therapies can create indefinite dependence if the
patient does not improve as hoped or develops an adverse
event (eg, stroke, progressive renal failure) that compromises
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options for anticipated definitive therapies. Such scenarios
are difficult for patients and clinicians and therefore must be
anticipated.
Temporary Mechanical Circulatory Support
Short-term circulatory support with intra-aortic balloon
pumps or other devices may be initiated when acute or
acute-on-chronic hemodynamic instability requires urgent
intervention to avoid permanent end-organ dysfunction or
death. It may be instituted with the hope of supporting a
reversible underlying condition, such as fulminate myocardi-
tis or right-sided heart failure after acute myocardial infarc-
tion. It may also be initiated in patients who might be
potential candidates for transplantation or permanent circula-
tory support, in whom (1) there has not been an opportunity
to appropriately evaluate their candidacy for more definitive
high-dependence therapies, (2) reversibility of end-organ
dysfunction is uncertain, or (3) contraindications to more
definitive therapies may resolve in the near future. If end-
organ dysfunction or contraindications do not resolve, a
decision will need to be made about discontinuation. To
whatever degree possible, these issues should be addressed
before the initiation of short-term support.
Positive Inotropic Agents
Intravenous inotropic agents are commonly initiated in the
acute setting for hemodynamic stabilization and to improve
end-organ perfusion. Use is most often anticipated to be
temporary, with the hope of either clinical improvement or
eligibility for more definitive therapies as above. Regardless
of intent, initiation of inotropic support for exacerbation of
chronic heart failure should be considered a significant
clinical milestone (Table 4). When patients fail to wean from
intravenous inotropic support, decisions arise concerning its
continued chronic use. Therefore, the goals of temporary
inotrope use should be established clearly before initiation,
and unexpected dependence on this therapy should prompt
direct discussions about overall goals of care and the limited
range of options available at this juncture.
The decision to arrange for chronic continuous infusions
after hospital discharge should be guided by the need for
symptom relief and patient preferences. Agreement on the
goals of therapy and various “what if” scenarios should be
reached before initiation. Nonrandomized data suggest that
the number of hospital days may decrease after initiation of
chronic inotrope infusion,77 with an increased risk of sudden
cardiac death.78,79 However, the majority of patients require
hospital readmission after initiation of chronic intravenous
inotropic therapy, even if begun with the hope of helping
patients to stay at home until death. The use of intermittent
infusions to control symptoms is currently not recommended
by American Heart Association/American College of Cardi-
ology guidelines (class III recommendation).17
A strategy to continue intravenous inotropic therapy for
symptom relief and return home should not trigger implan-
tation of an ICD, unless the patient is awaiting definitive
therapy such as transplantation. The majority of patients on
home inotropic infusions die by 6 months, and almost all
are dead by 1 year, most often of terminal hemodynamic
decompensation.
Renal Replacement Therapy
The prevalence of advanced kidney disease increases dramat-
ically with worsening heart failure,80 and measures of renal
dysfunction are strong predictors of adverse outcomes in
patients with heart failure (Table 3). Conversely, approxi-
mately 33% of individuals who commence hemodialysis have
a recorded diagnosis of heart failure, and their mortality rates
are significantly higher than patients who initiate dialysis
without a heart failure diagnosis (adjusted relative risk of 1.22
in the US Renal Data System).81 Dialysis in the setting of
advanced heart failure, especially in older patients with other
comorbidities or frailty, has been shown to add to patient
burden and in high-risk patients may not extend life.82,83
Therefore, the decision to initiate renal replacement therapies
(eg, hemodialysis, ultrafiltration) in patients with advanced
heart failure should only be made after a clear discussion with
the patient about the risks and benefits of dialysis on the
patient’s quality of life and prognosis.84
Transplantation and Mechanical Circulatory
Support: Exchange of Disease
Cardiac transplantation and mechanical circulatory support
offer the potential to fundamentally change the clinical course
of heart failure by exchanging it for surgical therapy and the
need to adjust to living with a different set of benefits, risks,
and burdens. In the case of transplantation, patients must
adapt to the risks of organ rejection and immunosuppression
and its side effects. For permanently implanted mechanical
circulatory support, patients are dependent on a device with
major complications of infection and stroke, as well as the
potential for continued symptoms and required therapies for
right-sided heart dysfunction. Thus, for eligible patients,
whether to pursue these therapies represents one of the most
difficult decisions that patients and clinicians can make.
However, these therapies are limited to a highly selected
group of patients. The use of cardiac transplantation is
constrained by a limited supply of donor hearts, a situation
that will not likely change in the foreseeable future. The use
of mechanical circulatory support may increase as the tech-
nology improves but is likely to remain inappropriate for the
majority of patients with heart failure because of the predom-
inance of heart failure with normal ejection fraction, multiple
comorbidities, or very advanced age.15,16 Detailed clinical
practice guidelines are available that address the use of these
advanced therapies.85–87
Noncardiac Procedures in the Patient With
Advanced Heart Failure
The risks and benefits of interventions for noncardiac condi-
tions may be altered significantly in patients with advanced
heart failure. When the likelihood of meaningful recovery
without the procedure is small, the increase in procedural risk
associated with heart failure may be considered acceptable.
Examples include both emergent (eg, laparotomy for perfo-
rated viscous) and urgent (eg, hip arthroplasty for fracture)
surgical procedures. Other procedures, such as knee replace-
ment for degenerative joint disease, must be considered
carefully in the context of patient preferences, because
complications of the procedure may or may not outweigh the
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potential benefit. Procedures should be discouraged when
they do not offer a tangible improvement in quality of life (eg,
repair of asymptomatic abdominal aortic aneurysm). Place-
ment of permanent peritoneal and pleural catheters for the
control of volume status is not indicated unless incorporated
into a comprehensive palliative plan of care. Similarly,
routine preventive care screening tests (eg, mammography,
prostate-specific antigen) are typically not appropriate in the
context of a significant competing risk of mortality caused by
advanced heart failure, yet such tests are frequently ordered at
the end of life.88
Anticipating Decisions for Unanticipated Events
The process of clarifying preferences for cardiopulmonary
resuscitation, intubation, feeding tubes, implantable defibril-
lator deactivation, intensive care unit transfer, and other near
end-of-life interventions before the occurrence of a near-
terminal event or acute-on-chronic decompensation is an
important aspect of shared decision making. There is litera-
ture on the type and scope of these discussions,89,90 with
suggestions to make them an annual event in routine medical
care.60(p73406) Such anticipatory discussions should include
advance care planning guided by the concept that it is proper
to “plan for the worst while hoping for the best.” It is also
crucial for the care team to make clear that clinician aban-
donment will not occur; that is, the clinicians will work with
the patient and family in downstream decision making and
management.
Palliative Care
Palliative care is interdisciplinary care aimed at improving
quality of life for patients by preventing and relieving
suffering and supporting families.91 As such, it can be offered
simultaneously with all other appropriate medical therapies.
Palliative care is not synonymous with end-of-life care or
hospice but can encompass them as the disease advances.
Palliative care allows for continued disease-modifying ther-
apies while ensuring symptom relief and interventions that
address psychosocial, physical, and spiritual needs. This is
done in 2 ways: by treating symptoms and by ensuring that
patients ’ treatment plans match their values and goals.92–94
The process of shared decision making is a central tenet of
palliative care: that the patient and clinician reach an under-
standing about preferences for life-prolonging therapy, symp-
tom relief, pain control, and end-of-life care. Unlike hospice
care (“Use of Hospice Services”), the application of palliative
care is based on patient need rather than patient’s prognosis or
life expectancy.
Although data on palliative care in patients with heart
failure are limited, several guidelines and reviews recom-
mend integration of palliative care for all patients with
advanced heart failure.19,89,90 This can and should be done by
all clinicians involved in the care of these patients. However,
referral to a palliative care team should be considered for
assistance with difficult decision making and refractory
symptom management in advanced disease, even as patients
continue to receive disease-modifying therapies. Palliative
care teams can consist of physicians, nurses, social workers,
chaplains, and other professionals who work to ensure that
patient and caregiver needs are assessed and met. Because of
the complex and changing nature of heart failure and the
complexity of conversations as they change according to the
patient’s underlying heart disease, it is important to integrate
palliative care into the care of patients with heart failure
before they enter stage D. Even as patients are being
considered for transplantation, mechanical circulatory sup-
port, or trials of novel therapeutics and pharmacological
agents, palliative care can be increasingly integrated to ensure
that patients’ symptoms are appropriately controlled and that
patients understand the nature of these interventions, as well
as the full complement of alternative therapies.95,96 The
synergistic relationship between palliative care services and
the heart failure team for patients with mechanical circulatory
support has been reviewed recently.95
End-of-Life Care Planning
● Clinicians should take responsibility for initiating the
development of a comprehensive plan for end-of-life care
consistent with patient values, preferences, and goals.
● Deactivation of an ICD is desirable to avoid unnecessary
pain and distress for patients and families at the end of life.
● Active discontinuation of mechanical circulatory support is
often appropriate and necessary at the end of life.
Planning for Anticipated Death
Although the prognostic uncertainty inherent in heart failure
makes it difficult to accurately anticipate the end of life, some
patients enter a terminal phase of the disease that may be
relatively apparent to the patients and/or their clinicians. In
such situations, when the goals of care often transition from
a focus on survival to quality of life and ensuring a good
death, clinicians should take responsibility for initiating the
process of putting into place a comprehensive plan of care
consistent with patient values, preferences, and goals.
Passive Withdrawal of Therapies: Deactivation
of ICDs
The option and ease of ICD deactivation should be discussed
before implantation and again for major changes in clinical
status (Table 4) or transitions in goals of care.97 At present,
this is done only rarely, thus leaving many patients vulnerable
to inappropriate device discharge and unnecessary suffering.
A recent survey found that only 1 in 4 next of kin reported
that a physician had discussed device deactivation with their
deceased family member before death.98 In a nationwide
survey of 734 physicians, including 292 cardiologists, 60%
had fewer than 3 experiences discussing deactivation of ICDs
with patients and/or families.99 Concordant with those find-
ings, a national survey of hospices found that 10% of
hospices have a policy regarding deactivation of ICDs, and
50% of hospices had at least 1 patient who had been
shocked within the past year.100 For a device near its
end-of-battery life, the generator should not be changed
without careful review of whether or not active defibrillation
is consistent with overall goals of care and anticipated
duration of good-quality survival.
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Active Withdrawal of Therapies When Patients
Are Dependent on Them
Although the legal construct of patient autonomy does not
recognize different degrees of dependence on therapies to be
withdrawn, clinicians, patients, and families may view sce-
narios in which withdrawal leads to direct and rapid patient
demise as unique and emotionally difficult. Examples include
withdrawal of renal replacement therapy, feeding tubes, or
pacemaker support for patients dependent on cardiac pacing.
An increasingly common scenario is the withdrawal of
mechanical circulatory support devices, either temporary or
durable, in patients who are not expected to recover to return
to a quality of life they consider acceptable.95 The average life
span of a patient after implantable left ventricular assist
device (LVAD) placement has been increasing over time,101
but morbidity and mortality remain high. Estimated actuarial
survival in the HeartMate II destination therapy trial was 58%
at 2 years.102 With improvements in medical technology and
associated outcomes, patients maintained with mechanical
circulatory support may not only be susceptible to death
attributable to cardiovascular causes but to other life-limiting
disease as well. The discussion about discontinuing device
therapy should be part of the “what if” informed consent
process before implantation. Subsequently, although there are
no specific recommendations to direct when these therapies
should be discontinued, it appears that declining quality of
life, signs of other organ system failure, or an irreversible
catastrophic adverse event such as a major stroke or hemor-
rhage should trigger serious discussions about device deacti-
vation. In a recent small study of characteristics of patients
for whom mechanical circulatory support was electively
discontinued, the most common triggers for discontinuation
included sepsis, stroke, cancer, renal failure, and impending
pump failure.203 Despite the perception that LVADs may
impose special ethical dilemmas,91 the Patient Self-
Determination Act still broadly applies, giving the patient, or
their surrogate decision maker, full autonomy to withdraw
support.
Device deactivation can be performed in the hospital or at
home, attended by a device-trained individual (ventricular
assist device coordinator) and others as requested (hospice
nurse, chaplain, etc). Before device deactivation, a discussion
with the patient (if able to participate) and family about the
patient’s current condition and prognosis, changes in device
benefit profile, how the device would be stopped, how
symptoms would be managed, readiness to proceed, and
anticipated outcome (ie, rapid death) is valuable. Unlike
ICDs, which can be deactivated without immediate effect,
LVAD discontinuation can result in rapid decompensation
and expedite death, particularly with valveless continuous-
flow devices. The average time to death after device deacti-
vation is approximately 20 minutes, which indicates that a
thoughtful discussion and careful plan should be in place well
before the device is discontinued.71 This clinical scenario has
been likened to withdrawal of endotracheal intubation and
ventilatory support, although patients with LVAD support are
more likely to be awake and alert at the time of decision to
discontinue support. If patients are on multiple forms of
support (eg, mechanical ventilatory support and LVAD sup-
port, with an ICD also in place), a coordinated plan to
discontinue all of these therapies simultaneously is needed.
Use of Hospice Services
For patients approaching the end of life, hospice may be a
viable option to provide symptom care and supportive ser-
vices for patients and their families, while also ensuring that
patients are able to die in their preferred environment. To be
enrolled in the Medicare hospice benefit, 2 physicians or a
physician and a nurse practitioner (one of whom is often the
hospice medical director) must certify that the patient has 6
months to live if the disease follows its usual course, and the
patient must be willing to forego usual medical services
aimed at curing the underlying terminal diagnosis.104 Most
private insurers have a hospice benefit similar to that pro-
vided under Medicare. Although hospice is provided in a
variety of environments,105 it is most commonly provided for
patients at home with the goal of keeping them in their home
until death. Hospice can offer a number of benefits to
enrollees and their families, including interdisciplinary team
management, home visits, respite care, and provision of
medications and durable medical equipment. Hospice also
includes a nurse who can always be contacted to advise on
urgent symptom needs and provide reassurance that interven-
tions are appropriate.
Customized care plans may provide comfort and relief for
some patients unwilling to accept formal hospice support. In
many cases, patients feel they are “not ready for hospice,” and
these patients should be referred to palliative care to ensure
expert control of their symptoms, as well as support for the
family. Likewise, continued education about the benefits of
hospice and the fact that families are often more satisfied with
hospice care than care provided in the hospital may also help
elucidate its benefits.106 One study of Medicare beneficiaries
with heart failure who received hospice demonstrated a
longer survival (by 81 days) than for those heart failure
patients who did not receive hospice.107
Hospice services have been shown to improve patient and
family satisfaction with care. Families of those dying with
hospice services were more likely to rate their dying experi-
ence as “favorable or excellent” than those who died in an
institution or at home with only home health services.106
Fewer than half of all patients with heart failure receive
hospice. This is, however, a marked increase from 20% of
heart failure patients being enrolled in hospice a decade
ago.108 Appropriate timing of referral to hospice is important,
because the family’s perception of being referred “too late” is
associated with greater dissatisfaction and unmet needs.109
Communication and the
Decision-Making Process
● Trust is the basis for the collaborative shared decision-
making process.
● Early solicitation of values, goals, and preferences is
necessary to guide the range of possible therapy options
and decisions.
● Shared decision making is an iterative process that evolves
over time as a patient’s disease and quality of life change.
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● Assessment and integration of the emotional readiness of
the patient and family are vital to effective communication.
● Ask-Tell-Ask provides a useful framework for communi-
cating about prognosis and goals.
● Successful conflict resolution involves early recognition of
conflict unfolding, with a shift in focus from winning an
argument to trying to understand the reasons for conflict.
● Decision aids are tools that can enhance shared decision
making by presenting numeric data in more understandable
ways and assisting patients in clarifying their values.
Most patients and families want accurate and honest conver-
sations with their clinicians.110,111 One study found that 93%
of surrogate decision makers felt that avoiding discussions
about prognosis was unacceptable.110 Advanced heart failure,
with its high degree of prognostic uncertainty and complex
trade-offs in the choice of medical care, demands a thoughtful
approach to communication and decision making. Ideally,
these interactions are not 1-time events but occur as an
evolving series of discussions over time, particularly as a
patient’s condition changes. Such interactions may be diffi-
cult and time consuming, and they often require planning to
create a supportive environment for effective communication.
These discussions require careful attention to both mental and
emotional needs. Clinicians must determine how much quan-
titative information patients want about prognosis, compara-
tive risks, and benefits for both length and quality of life with
available therapies. At the same time, clinicians must attend
to the emotional nature of conversations with patients to build
trust, clarify core values, and allow for sharper focus on the
information. Here, we provide an overview of the tasks and
skills, along with sample phrases, that can create high-quality
shared decision making (Table 7).
Communication Is Desired, Beneficial,
and Dynamic
Open, clear, and accurate communication with patients with
heart failure is important for several reasons. First, the
majority of patients with serious illness want information
about their illness and to be included in the decision making
process.116–118 Second, when clinicians have conversations
with patients about their prognosis and desires, patients are
more likely to receive care that is aligned with their goals and
preferences.119–121 These conversations also improve the
patient-clinician relationship.122 Finally, when conversations
occur, families of deceased patients have better outcomes in
terms of the manner in which they cope with loss of their
loved one, as well as their own psychological out-
come.110,121,123 One randomized trial of an advanced care
planning intervention demonstrated that the intervention in-
creased the likelihood that the patient’s preferences were
known and followed (86% versus 30%, P0.001) and de-
creased family members’ stress, anxiety, and depression.121
Although many of the data about benefits of communication
in patients with advanced illness are from the field of
oncology, the evidence base demonstrating similar results in
cardiology is increasing.124
The biological reality of heart failure makes communica-
tion particularly difficult for 2 reasons. First, heart failure is
characterized by unpredictable periods of acute illness, fol-
lowed by improvement in symptoms and function (Figure
1).19,21,125,126 Attending to this uncertainty involves both
acknowledging the cognitive aspect of the conversation (eg,
explaining to patients and families the unpredictable nature of
illness and recognizing the inability of modern medicine to
accurately predict life expectancy), while simultaneously
addressing the complex emotions associated with the “roller
coaster” of heart failure (eg, fear, anxiety, and uncertainty).
Second, the chronic nature and unpredictability of heart
failure require that communication be viewed as an evolving
series of dynamic conversations that take into account the
overall goals of the patient and family, the current state of
heath, and the shifting balance between benefits and burdens
of any treatment or test that is either currently being used or
that is being considered. Patients’ preferences may change
over time as their illness progresses and their experience with
the disease changes, which further underscores the impor-
tance of an ongoing dialogue with patients and their fami-
lies.39,56,127 For example, in 1 study of 936 patients with
advanced heart failure, 19% had changed their preferences for
resuscitation within 2 months.56
To communicate effectively, clinicians must both deter-
mine and then readdress over time patients’ understanding of
their heart failure and their goals and treatment preferences
(Table 4 for timing) and then determine how to have these
conversations within the scope of clinical care. For example,
when a patient is being seen for their first office visit after a
hospitalization for heart failure, it may be useful to readdress
goals of care from a global perspective, asking how the
patient’s thoughts about his or her heart disease have changed
since the last hospitalization. In the case where emergent
decision making is needed, the clinician might acknowledge
how the conversation was last addressed and then bring up
the specific emergent decision(s) at hand.
A Roadmap to Guide Conversations
Physician training in the conduct of these discussions is
limited and needs to be fortified.128,129 Furthermore, the work
of shared decision making belongs not only to physicians but
to other members of the healthcare team as well, specific to
their roles and responsibilities. Although additional training
and mentored experience are clearly desirable, this section
provides an introductory roadmap of how to effectively
communicate with patients with advanced heart failure to
facilitate the shared decision-making process. It is meant to
represent an idealized version of communication, with the
realization that this must be balanced with other competing
responsibilities and clinicians’ limited time. The goal is to
offer effective strategies to improve conversations and deci-
sion making by demonstrating how complex conversations
can be broken down into discrete elements, making them
easier to accomplish. Not all conversations will include all of
these elements every time. The goal is to offer a simple
outline (along with some helpful phrases and tools) that may
make conversations simpler for the busy clinician. More
comprehensive explanations about how to communicate with
patients with advanced illness are available.94,112,130
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Where Are We on the Road? Ask-Tell-Ask to Determine
What Patients Know and Want to Know
Before one can embark on conversations with patients and
their families, it is important to establish the right context for
the conversation. This includes asking whether the patient
wants to have the conversation by themselves or would like
other individuals present, remembering that patients often
define family in a myriad of ways. Creating the right setting
also involves ensuring that the right clinicians are present, or
at least have been consulted, before the conversation begins.
Table 7. Core Tasks, Skills, and Sample Phrases to Improve Clinician-Patient Communication in Advanced Heart Failure
Steps in the Roadmap Elements of the Step Sample Phrases
Establish the setting and
participants
Determine who should be present and ensure
that all appropriate clinicians are present as
well
“In preparation for our meeting tomorrow, I’m going to have
the cardiothoracic surgeon there to be a part of our
conversation. In terms of your family or support network, who
is it important that we make sure is there?”
Determine what patients know and
want to know
ASK what patients/families know “Tell me about your heart disease; how have you been doing
lately?”
“What is your understanding of what is occurring now and
why we are considering the treatment that we have been
discussing?”
ASK what patients/families want to know “Sometime patients what to know all the details, whereas
other times they just want to know a general outline. What
kind of person are you?”
“How much information would you like to know about what is
happening with your heart disease?”
TELL the patient/family the information in a
sympathetic and thoughtful manner while
also clearing up any misconceptions or
unanswered questions
“I think you have a pretty good understanding of what is
happening with your heart, but there are a few points I’d like
to review and clarify”
ASK the patient or family to repeat back the
information that has been delivered
“Now that I’ve clarified a few things about your illness, I want
to make sure you understand what I’ve said. Tell me in your
own words what we’ve been talking about”
Establish goals and preferences Use open-ended questions to gain
understanding of the patient’s values to
determine what is most important to them
“Help me to understand what is important to you. Some
patients say they want to live as long as possible, regardless
of quality of life. Sometimes patients tell me they are worried
that they will be in a great deal of pain or have other
uncontrolled symptoms. What is important to you at this point
in terms of your health care?”
“What are you hoping for?”
“What is important to you now?”
“What is your biggest concern right now?”
“When you think about the future, what are the things you
want to avoid?”
In cases in which the patient is not involved in the
conversation, a useful phrase might be, “What would your
loved one say right now if he or she were hearing what we
are discussing?”
Work with patient and family to
tailor treatments and decisions to
goals
Tailor explanation of benefits/burdens of a
particular therapy based on goals established
“I think I understand what is important to you now, and it
helps me better explain to you the decisions and treatments at
hand now. I’d like to take a moment to review the benefits
and burdens of each of the treatments based on what you’ve
said is important to you at this point”
Be willing to make a recommendation based
on the patient’s goals
“Would it be helpful if I made a recommendation based on
what you’ve said the overall focus of care should be now?”
“Based on what you have told me, if you get sicker and need
to go back on a breathing machine again to stay alive, that is
very unlikely to provide the kind of life you want to lead.
Therefore, I think you should not go back on those machines”
Acknowledge that there is uncertainty in the
course of heart failure
“One of the most difficult things about heart disease is that we
can never know for sure exactly what will happen in the next
(hours, days, weeks, etc). We must make our best guess and
decide what to do based on that information. If things change,
we can always readdress this discussion at any time in the
future”
Adapted from others.112–115
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The individual leading the meeting ideally will have spoken
to all the clinicians involved in the care of the patient so all
points of view are represented and everyone is “on the same
page” in terms of the illness and timely decisions.
Begin by asking the patient and family what they know and
want to know. In this system, often called Ask-Tell-
Ask,113,131 the clinician begins by asking patients and their
families both what they know about their disease or the
treatment being considered and how much information they
want. Nearly 80% of patients want information about their
illness, and this number rises as patients’ disease progresses.
A Cochrane review of decision-making trials demonstrated
that as patients learn more about the risks and benefits of
therapies, the proportion preferring to take an active role in
decision making increases to 85%.132 However, the only way
to assess patients’ wishes is by asking and providing the
patient this locus of control, which generates trust that is
essential for collaborative decision making. An explicit way
to ask is, “Would you want to know everything about your
illness or the treatments we are considering, even if it wasn’t
good news?” When patients and families express they do not
want certain information, this should be explored further,
with the explanation that information may be helpful for
improving their understanding and to make sure that the
decisions are consistent with the patient’s wishes. Denial and
other defense mechanisms should not be ignored but instead
carefully addressed and managed (“Emotional Roadblocks”
below).
Once basic expectations for information exchange have
been established, clinicians convey information to the patient
and family in a clear and thoughtful manner, while also
clearing up any misconceptions or unanswered questions they
might have. This is the “Tell” in Ask-Tell-Ask. It is important
to initially focus on the larger picture of the patient’s health,
because the ability to cognitively hear information, particu-
larly in stressful situations, is limited.133 Giving all of the
medical details may easily overwhelm the patient and may
also lead him or her to focus on details that ultimately are not
critical. The information should be delivered in simple
language with frequent pauses to assess patient and family
understanding.
The last “Ask” of the “Ask-Tell-Ask” process involves
asking the patient or family to repeat back the information
that has been delivered, to assess their understanding. This
allows the clinician to determine the level of understanding
the patient and/or family have and clarify any elements that
may remain unclear in their minds.
The Ask-Tell-Ask technique is meant to be iterative and
can be applied to many different levels of the process of
communication. For increasingly complicated treatments and
situations (eg, destination-therapy mechanical circulatory
support), Ask-Tell-Ask is likely to be an extensive recurrent
process that will occur over multiple encounters with the
patient and family. Particularly complicated decisions may be
augmented with decision aids (below).
Where Does the Patient Want the Road to Go?
Establishing Values, Goals, and Preferences
One of the core elements of good communication is that it
assesses patients’ values, goals, and desired outcomes, thus
allowing treatments and care to be as closely tailored to those
desires as possible. This is especially true in light of the fact
that physicians are often wrong about patients’ desires for
care.56 Optimal communication with patients with advanced
heart failure does not begin with questions about treatments.
Asking a patient during a routine office visit, “Do you want
us to try and restart your heart?” is unlikely to be an effective
starting point. This task is especially difficult because it
involves weighing desired outcomes that may be contradic-
tory (eg, avoiding severe disability while maximizing sur-
vival). This step then not only outlines what the patient hopes
for but also considers complex trade-offs and situations the
patient might consider a “fate worse than death.”
Open-ended questions to gain insight into the patient’s life
and values are a useful method for initiating this portion of
the conversation. Examples include, “What is important to
you now?” or “What are you hoping for?” Another technique
involves asking patients to discuss what is important in life
outside of the hospital; this helps the clinician to understand
what patients are doing in day-to-day life, how much patients
value those tasks, and how patients view those tasks in the
future. It also may be useful to inquire about a patient’s
worries or concerns, using questions such as, “What is your
biggest concern right now?” or “When you think about the
future, what are the things you want to avoid?” In cases in
which the patient is not involved in the conversation, either
because of illness severity or because the patient chooses not
to take part in the conversation, a useful phrase might be,
“What would your loved one say right now if he or she were
hearing what we are discussing?”
When advanced heart failure patients discuss their goals,
they often discuss quality of life; that is, they typically are not
only concerned about how long they will live but also how
well they will live. This is especially true given that poor
quality of life (limited ability to perform daily activities,
significant symptom burden, emotional distress, and social
isolation) is often reported by patients with advanced heart
failure.42,134,135
After clarifying the patient’s goals, it is often useful to
summarize what has been expressed. In addition to ensuring
that the clinician has heard and understood these hopes
correctly, doing this also demonstrates care for the patient and
that the clinician is attending to their needs. This may start
with phrases such as, “Let me see if I understand what you are
saying.”
Ensuring the Road Is Aligned With the Desired
Destination: Tailoring Treatments to Goals
After goals have been clarified, the conversation can then
move to discussing the role of specific treatments within the
context of the desired outcomes. This involves working with
the patient and family to (1) summarize the range of medi-
cally reasonable treatments for this particular patient at this
particular time and then (2) explain the risks and benefits of
each treatment option within the personalized rubric of goals
and desires set forth by the patient and the family. Working
within this context, the clinician helps the patient understand
which treatments are most appropriate or inappropriate, based
on their likelihood of getting the patient to the desired
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outcome. This is, in fact, the core of shared decision making:
The clinician does not dictate treatments, nor does the burden
of the decision rest solely with the patient and family. Instead,
the 2 parties work together to determine which options or
treatments make the most sense given the patient/family’s
desired outcomes in the context of the current clinical
scenario. In some cases, patients or families may be able to
come to a decision on their own once the treatments and
probable outcomes have been presented. However, even in
these cases, families report they want to know what the
physician would recommend.136 In other cases, the patient
and the family may signal they want more guidance (eg,
“What would you do if it were your mother?”) In these cases,
it is appropriate to offer a recommendation based on the
patient’s stated goals (eg, “Given what you have told me
about what is important to her, I think the treatment that
makes the most sense to get her to the desired goal is ….”).
Uncertainty about outcomes of specific treatments and out-
comes should be communicated honestly and openly with
patients and their families.
Tips for Navigating Barriers
These complex conversations with patients and families face
serious challenges and barriers. This section outlines some of
those challenges to inform busy clinicians and increase their
awareness of them. Whenever possible, solutions and ap-
proaches with which to navigate these potential roadblocks
are offered. These elements may be encountered (or solutions
utilized) at any point in the decision-making process and thus
operate in conjunction with the roadmap described above.
Acknowledging Emotional Roadblocks
Difficult decision making can stimulate complex emotions.
Engaging patients in selecting treatments aligned with their
informed goals and values requires that clinicians not only
present the options clearly but that they also be attentive to
patients’ emotional needs. Patients are ill, caregivers are
exhausted, and there may be a tremendous amount of fear,
anxiety, stress, and perceived loss of control.137 Neuropsy-
chological studies have shown that when people are emotion-
ally reactive, cognitive information is not processed accu-
rately.130,133 One small study of family members of patients in
the intensive care unit showed a relationship between com-
munication styles and rates of anxiety in caregivers.138
Attending to patients’ emotions may improve their ability to
process cognitive data and make better decisions. In addition,
responding empathetically has been show to strengthen the
patient-clinician relationship, increase patient satisfaction,
and make patients more likely to disclose future worries.139
The first element of developing an emotional language for
conversations is to recognize that patients are having an
emotional reaction to the news that is being delivered and
then learning to address the emotional content of the conver-
sation. In one study of communication with family members
of patients dying in an intensive care unit, clinicians missed
opportunities to respond to the emotional content of the
conversation in 29% of the conversations.140 Although at
times, patients’ emotional reactions may be clear (especially
when they use words such as “scared” or “angry”), at other
times the exact emotional content of the discussion may be
more veiled, such as when a patient or family says, “I don’t
know if I can handle this anymore.” If patients or families
keep raising the same issue repeatedly during a meeting, it
may indicate that they are having a reaction to an issue that is
so strong that it interferes with their ability to process
information. For example, when patients ask a question such
as, “How did this happen?” it may often be a clue that there
is an emotional component to the information and that what
is needed is a query about the patient’s emotions and not a
cognitive response explaining the cause of a disease or a
complication. Addressing the reaction of patients and their
families to serious illness is a metric that has been proposed
to measure the quality of palliative care programs.93
Once the clinician has recognized that there is an emotional
component to the patient’s or family’s reaction, the next
essential skill is to respond to it. Although there are data
demonstrating that as little as 40 seconds of empathetic
comments in conversations can improve patient and family
outcomes related to communication, clinicians often need
assistance in finding the right words to express their empathy
for patients in the course of these complex conversa-
tions.141,142 One useful mnemonic device that can help clini-
cians respond empathetically in conversations is the mne-
monic N-U-R-S-E.141 As explained in Table 8, NURSE
stands for Naming the emotion expressed in the conversation,
demonstrating Understanding of the emotion, Respecting the
emotion displayed by the patient or family, Supporting the
patient/family, and Exploring the emotion in the context of
the discussion. This assists clinicians in demonstrating verbal
empathy and ensures that the complex emotional components
of the conversation are addressed. More comprehensive
reviews regarding the importance of acknowledging patient
and family emotions have been published.143,144
Table 8. Using the N-U-R-S-E Mnemonic to Help Express
Verbal Empathy When Communicating With Patients With
Advanced Heart Disease
Technique Sample Language
Name the emotion You seem worried about what will happen if
we don’t implant the LVAD. Can you tell me
more about that?
Understand the emotion I see why you might be fearful of
proceeding with the transplant. Can you
help me understand what you’re afraid of?
Respect the emotion You have shown a lot of strength up to this
point. Tell me more about what keeps you
going
Support the patient Whether or not you choose to have the
procedure, I want you to know that I will
continue to be your cardiologist and will
take care of you no matter what happens
Explore the emotion You mentioned earlier that you’re concerned
about what this worsening of your shortness
of breath might mean. Can you tell me
more about your concerns?
LVAD indicates left ventricular assist device.
Reprinted from Back et al,113 with permission of the publisher. Copyright ©
2005, Wiley & Sons.
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Depression and Anxiety
Depression and anxiety are common in patients with heart
failure, with prevalence rates ranging from 13% to 77% and
from 50% to 70%, respectively.145–147 Furthermore, preva-
lence rates for depression are almost 4-fold higher in patients
with New York Heart Association functional class IV versus
class I heart failure and also vary by self-reported symptom
severity and health status.148 These indicators of mental
health status may affect the decision-making process. Depres-
sion is associated with impaired cognition and so can inter-
fere with processing of information, memory, and executive
function, which can affect decision making, especially in
older adults.149–151 Anxiety, as noted above, can alter pro-
cessing of information because of emotional reactivity. Thus,
in patients with advanced heart failure, these barriers to
decision making need to be identified and addressed to
enhance discussions about therapeutic options. Screening for
depression and anxiety, followed by pharmacological and
nonpharmacological interventions (including psychological
and/or psychiatric consultation), may be appropriate.
Limitations of Cognition, Literacy, and Numeracy
Current evidence suggests that in general, patients have a
poor understanding of their medical interventions and that
their preferences are not driving decisions.7 A survey of 3010
adults revealed that people were relatively unaware of the
risks of 9 common medical conditions. For example, of
patients taking a cholesterol medication, 38% did not know
that the treatment was lifelong, and 83% could not correctly
identify the most common side effect (muscle pain).152 In the
case of ICDs, more than half of patients overrated the benefits
of ICD therapy by 500%, thinking that 50 of 100 lives
would be saved by the ICD therapy over the next 5 years (the
actual estimate is closer to 5–10 per 100).153 In the case of
elective percutaneous coronary intervention, patients signifi-
cantly overestimated the benefits; one study demonstrated
that 88% of patients believed that percutaneous coronary
intervention would reduce the chance of a recurrent myocar-
dial infarction and 82% believed that it would reduce mor-
tality,154 despite clinical trial data that elective percutaneous
coronary intervention has no effect on recurrent myocardial
infarction or mortality.155 Another study demonstrated that
fewer than half of the patients could recall at least 1
complication of percutaneous coronary intervention despite
the fact that most of them expressed a strong interest in
participating in decision making. Together, these data suggest
a need for improvement in the decision-making process.156
Cognitive impairments compound difficulties with com-
munication, comprehension, and decision making. Mild cog-
nitive decline is seen in 25% to 50% of adults with heart
failure.157 A recent comparison of heart failure patients,
healthy participants, and medical patients demonstrated that
heart failure patients had poorer memory, psychomotor
speed, and executive function than the other participant
groups.158 Almost one quarter of the heart failure patients had
deficits in 3 domains of neuropsychological functioning.
Those patients most likely to experience cognitive decline
were those with the worst heart failure severity.
Limitations in health literacy and numeracy further inter-
fere with understanding and integration of the information
discussed as it relates to decision making. Health literacy is
the degree to which people have the capacity to obtain,
process, and understand the basic health information and
services needed to make appropriate health decisions.159
Nearly 10% of the population is functioning at below basic
literacy levels.160 Those most likely to be in the below basic
level had less than a high school education, spoke no English
before starting school, or were Hispanic, black, 65 years of
age, or had multiple disabilities. Only 12% of the US
population had the skills needed to manage their own health
care proficiently.161
Not surprisingly, low health literacy is associated with poor
self-care162–164 and increased mortality in older adults with
chronic illnesses such as heart failure.165–167 To offset these
poor outcomes, a recent scientific statement from the Heart
Failure Society of America specifies that clinicians must
recognize the consequences of low health literacy, screen
patients at risk, document literacy levels and learning
preferences, and integrate into practice effective strategies
to enhance patients’ understanding.168 Furthermore, com-
municating numeric risk in a graphic form has also been
shown to improve comprehension among patients with
difficulties in literacy and numeracy132 (“Patient Decision
Aids” at http://decisionaid.ohri.ca/169 for examples).
Family Dynamics
Family dynamics can be a barrier to negotiating goals of care.
A recent survey of elders (mean age 83 years) and their adult
children (mean age 53 years) revealed that although most
family units had discussed end-of-life preferences, important
barriers to such discussions included fear of death, trust in
others to make decisions, family dynamics, and uncertainty
about preferences.170 Those factors that facilitated the discus-
sion were acceptance of the reality of death, prior experience
with death, religion or spirituality, and a desire to help the
family. In addition, there are significant psychological bur-
dens associated with surrogate decision making.170 Interest-
ingly, previous discussion with their loved one about goals
appeared to mitigate these burdens, providing an additional
reason to raise these issues with both the patient and family
early in the course of the illness.
Culture and Religion
Cultural and religious differences in patient preferences are
known to exist.171 Awareness of cultural and religious differ-
ences can facilitate understanding of patient choices when
discussing treatment options, especially when patients decline
evidence-based therapies that healthcare professionals per-
ceive as offering more benefit than risk. Although clinicians
are not expected to be experts in cultural or religious issues
relating to decision making, it is important that they be aware
of the influence of these elements on decision making.
Conversely, clinicians should also be warned against making
assumptions about patient preferences based on perceived
cultural or religious expectations. Clinicians should speak
candidly with patients using the strategies recommended.
Referral to palliative care, chaplaincy, or social work services
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may help reveal existing religious and cultural differences as
they relate to the decision-making process.
Language Differences
According to the US Census Bureau, the population speaking
a language other than English at home has increased steadily
for the past 3 decades.172 The number of languages and
dialects spoken across the country presents major challenges
to clinicians seeking to have a meaningful conversation about
therapeutic options and end-of-life issues. Even among those
patients who have learned English, when English is the
second language, the subtleties and nuances of a discussion
may be missed. Interpreters are often needed, which can be
challenging in terms of finding someone linguistically capable,
available, and sufficiently sensitive to communicate both the
content and the tone.173 Often, clinicians rely on family members
to interpret for them, but family members have their own needs
and emotions surrounding these conversations, which makes
their use as interpreters potentially problematic.174
Time
One of the largest barriers to these conversations is the
time-intensive nature of these conversations, coupled with the
time constraints faced by both patients and clinicians in a
busy medical setting. Currently, clinicians can bill solely on
the basis of time when 50% of the encounter (inpatient
or outpatient) is spent on counseling the patient/families or
coordinating care. Recent efforts aimed at making it easier for
providers to be reimbursed for conversations about goal
setting were ultimately abandoned for a variety of reasons.175
Because of the complexity of these conversations, however,
realignment of incentives to encourage providers to have
these conversations and improve their skills for doing so is
necessary and vital.
Resolving Conflict
In some cases, an intervention desired by a patient may
appear discordant with the patient’s stated goals and/or
medical realities, and clinicians must explain why it is not
warranted. This is particularly difficult in our national culture
of entitlement and denial of morbidity and mortality. Clini-
cians must work with patients and their families to explain
why a particular treatment is inconsistent with the overall
goals of care, using patients’ preferences as a rubric for why
the treatment is not appropriate. These discussions can be
emotionally charged and adversarial and may require consid-
erable time. Given both the complexities of these conversa-
tions and their considerable length, formal involvement of
palliative care teams has been shown to improve patient and
caregiver satisfaction, effectively control symptoms, and
decrease costs for patients with advanced disease.176–179
There are 3 key elements that characterize discussions
about not providing a therapy. First, the emphasis of the
conversation should be on what treatments will still be
provided that will help accomplish the patient’s goals. This
ensures the patient does not feel abandoned. Second, one
should attend to the emotion behind the request. For example,
“I wish I could tell you that doing [specific treatment] will
accomplish the goals that you have outlined, but I’m sorry to
have to say that it will not.” In general, the “I wish” statement
can be beneficial in terms of acknowledging the emotional
impact on patients of no longer having options for various
therapies (ie, “I wish things were different”). Third, some-
times the patient or family has either misheard or misinter-
preted the data that was presented, so it may be helpful to
clarify what further information is needed to reconcile any
inconsistencies (eg, “Tell me more about how you think CPR
would help you”). By asking patients to clarify their reason-
ing, the clinician can more effectively address misunderstand-
ings and inconsistencies. In this manner, the clinician attends
to the emotions to better understand what is behind the
request and then uses the NURSE strategy to acknowledge
the emotion, rather than creating conflict with patients and
their families about the treatment itself.
Decision Support to Assist With Particularly
Difficult Conversations
In many cases, the decision at hand may be particularly
complex or may require assistive methods to help patients
and caregivers understand the potential outcomes and risks.
In these cases, a decision support intervention, such as a
decision aid or a decision coach, can help enhance conversa-
tions between patients and clinicians.
“Decision aids” are tools that help patients and caregivers
become involved in decision making by providing informa-
tion about the options and outcomes and by assisting patients
in clarifying their personal values.10,180 Decision aids come in
various forms, including booklets, pamphlets, videos, and
Web-based systems,169 and are designed to complement, not
replace, a clinical encounter. They can be conceptualized
broadly as either aids to assist the patient during or indepen-
dent of the face-to-face encounter.10 A key difference be-
tween decision aids and a simple information pamphlet is that
decision aids do not simply provide data about the anticipated
risks and benefits but also provide guidance to help patients
clarify their personal values and make a decision.181 Decision
aids can also help patients clarify their values through a
simple pros and cons list or an “imagined future” exercise.182
Decision aids attempt to present probabilities of the risks and
benefits in ways that patients can understand. In fact, recent
innovations have included the calculation and presentation of
patient-specific outcomes generated from multivariable mod-
els (such as those listed in Table 3, among others), in routine
clinical care. In the setting of informed consent for angio-
plasty, such a tool was demonstrated to improve patients’
understanding of the risks of treatment, decrease anxiety, and
improve satisfaction.183 As new models are created that
estimate a broader range of outcomes that are important to
patients, this concept can be further developed, tested, and
applied in advanced heart failure. A Cochrane review of 55
randomized trials of patient decision aids demonstrated that
decision aids improved patient knowledge, reduced deci-
sional conflict, increased patients’ participation in decision
making, and reduced the number of people remaining unde-
cided with no associated adverse health outcomes.184 How-
ever, only 1 trial in this Cochrane review was related to
ischemic heart disease, and none were related to heart failure.
The fact that substantial evidence suggests that decision aids
help patients make better decisions combined with the fact
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that patients with heart failure face a multitude of compli-
cated decisions indicates that this is an area in need of
significant development and research. The work on develop-
ing decision aids should begin with the higher-stakes deci-
sions, including use of ICDs, inotropes, LVADs, and
transplantation.
An alternative model to decision aids is the “decision
coach,” a trained professional, often a nurse, who assists
patients in making medical decisions by helping them prepare
for a consultation and by empowering them to ask questions
of their provider.185 Early research suggests that coaching
interventions may have modest effects on knowledge and
participation in decision making.186 The Ottawa Decision
Support Guide is available for download and can be used for
decision coaching (http://decisionaid.ohri.ca/decguide.html).169
Although the use of coaches has not been studied in
patients with advanced heart failure, nurses and other
providers working with heart failure patients could be
trained in decision coaching techniques.
Directions for the Future
● Changes in organizational and reimbursement structure
will be necessary to reward and integrate decision making
into the delivery of patient-centered health care.
● Mechanisms for standardizing, integrating, and distributing
the work of shared decision making among the healthcare
team should be developed and evaluated.
● Research to better define comparative functional and
quality-of-life outcomes for the major therapies is vital to
truly inform and align decision making with patient goals.
● Caregiver burdens and expectations should be assessed for
all therapies and included as components of decision
making.
● Content and form of decision aids should reflect contem-
porary outcomes data and interactive technology.
● Skill sets for communication and shared decision making
should become part of standard curriculum and training for
providers.
● Future research is needed in a variety of areas related to
shared decision making, including effective communica-
tion training, decision support interventions, group visits,
health-related quality-of-life measures, and caregiver bur-
den, needs, and outcomes.
Need for Structural and Reimbursement Changes
to Emphasize Shared Decision Making
Many busy clinicians may dismiss the above recommenda-
tions as impractical given the considerable time needed to
complete the detailed communication processes outlined
above. The diverse tasks of physicians, nurse practitioners,
and physician assistants involved in primary care, general
cardiology, and advanced heart failure management limit the
capacity to conduct thorough prognostication, communica-
tion, and shared decision making for the various patient-
centered outcomes, diverse patient and family preferences,
and array of treatment options available to these complex
patients. Yet, the unique role of clinicians demands that they
assume the primary responsibility for advancing shared de-
cision making and promoting patient-centered care.
As such, the routine conduct of these activities must be
efficiently integrated into routine care. The more clinicians
perform shared decision making, the better they will be at
making it a natural part of their routine practice of care.
Patients and families could be prepared for important discus-
sions before the clinic visit through a variety of possible
mechanisms, facilitating better use of time for the busy
clinician. Furthermore, palliative care services are an instru-
mental resource in helping with the more complex decisions
and major milestones that arise in the course of advanced
heart failure care. Multidisciplinary team-based care is nec-
essary. Guidelines for the most dramatic therapeutic options,
for instance, transplantation and mechanical circulatory sup-
port, already recognize the need for coordinated interdisci-
plinary care.85,87 Only through diverse inclusion of healthcare
providers—nurses, nurse practitioners, physician assistants,
primary care physicians, medical ethicists, chaplains, social
workers, and others—can this shift adequately take place. A
cultural change, particularly within cardiology but also more
broadly, is necessary.
However, increased efficiency and dedication on the part
of healthcare providers can only partially address the need for
quality decision making. Ultimately, the US healthcare sys-
tem primarily reimburses clinicians for doing things, not for
deciding which things should and should not be done; both
activities are time consuming and involve the expertise of a
skilled clinician, yet only one is valued financially. For a
healthcare system that has been criticized for overutilization,
placing a greater emphasis on the shared decision-making
process is likely to serve as a corrective force to achieve
greater value from the system.187 A start would be to
reimburse clinicians more equitably for conducting a com-
prehensive annual heart failure review, which would include
voluntary advanced care planning.60(p73406) Unfortunately,
attempts to specifically reimburse clinicians for these types of
activities have met resistance for a variety of reasons.175 Until
these policy differences can be reconciled, actions like those
by the Institute of Medicine to make shared decision making
1 of the pillars of quality care equate to an unfunded mandate
in clinician time and energy.
Training Programs to Improve Communication
With Patients With Heart Failure
Skills required to support patients in decision making are not
adequately taught in training programs.129 Multiple studies
have shown variation and deficiencies in the ability of
clinicians to communicate with patients and address end-of-
life issues.188–190 Given the important yet difficult task of
communication in clinical practice, improving communica-
tion should be a core element of the “performance-based”
training and certification processes adopted by the Accredi-
tation Council for Graduate Medical Education. The recent
establishment of the secondary subspecialty of advanced
heart failure and transplant cardiology191 by the American
Board of Medical Specialties is an opportunity to formally
add communication techniques and shared decision making
to the training and certification process for physicians dedi-
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cating their career to the care of these patients. Similar
training is especially important for general internists and
advance practice nurses who will be caring for a large number
of patients with advanced heart failure. Requirements for
institutional certification, such as The Joint Commission’s
Advanced Certification in Heart Failure program,192 offer yet
another opportunity to emphasize formal processes that en-
hance shared decision making.
Several interventions have successfully improved commu-
nication skills for clinicians, particularly with regard to
end-of-life care. Studies on the Education for Palliative and
End-of-Life Care Project, a standardized multicomponent
curriculum with an emphasis on improving communication,
demonstrated an improved physician knowledge base and
confidence in caring for patients at the end of life.193,194
Likewise, work with oncologists found that a program that
combined training, role play, and individualized feedback
improved participants’ communication patterns, outcomes,
and transitions across healthcare settings.195,196 Some
nursing-centered interventions have been shown to be suc-
cessful in changing nursing practice and improving outcomes
for patients. The End-of-Life Nursing Education Consortium
(ELNEC) program uses a train-the-trainer model, whereby
nurses who complete the program are considered trainers who
then go back to their home institutions and teach other nurses
the core content aimed at improving care for patients with
advanced diseases. Across the country, more than 4500
nurses have been enrolled in ELNEC,197 and data from
ELNEC have shown that the program improved nursing
attitudes and knowledge about end-of-life care.198
The successful programs to improve communication skills
in end-of-life care provide a template for comprehensive
“communication” training of heart failure clinicians and need
to be expanded to the general physician and midlevel pro-
vider community. Additionally, mentoring trainees in patient
and family meetings can help to ensure that clinicians have
obtained the necessary skills to effectively communicate with
heart failure patients and their families.
Future Research Directions to Improve
Communication With Patients With Heart Failure
Methods for educating clinicians regarding communication
and shared decision making remain early in their develop-
ment. Useful decision aids for commonly encountered med-
ical decisions in heart failure are also largely underdeveloped
or unavailable. One company has developed decision aids for
patients considering ICD and CRT therapy (http://
www.healthwise.org),198a and another has developed a gen-
eral decision aid for patients with heart failure (http://
www.informedmedicaldecisions.org),198b but these have not
been studied formally in real-world settings. Several recently
funded National Institutes of Health grants are designed to
develop and evaluate decision aids among patients with heart
failure, with the recognition that the results of this work are
several years away.
At a more basic level, our understanding of how patients
with advanced heart failure make choices is limited. There is
also no consensus in the literature on the best way to measure
whether a medical decision was a “good” one.199 Decisional
quality, defined as “the extent to which the implemented
decision reflects the considered preferences of a well-
informed patient,”200 is emerging as another possible measure
to assess the quality of decision making, but validated
measures to quantify decisional quality are in the early
developmental stages.200 An ideal metric to measure decision
quality would include domains in knowledge and values and
a way to measure value-treatment concordance. Despite
lingering questions, decision quality measurement is gaining
popularity, and some have proposed that measures of decision
quality be included as part of the larger pay-for-performance
agenda.187 The Patient Protection and Affordability Care Act
calls for “the development of quality measures that allow for
assessment of the experience, quality, and use of information
provided to and used by patients, caregivers, and authorized
representatives.”13
The role of palliative care in patients with advanced heart
failure has been far less developed than in cancer,201 and
further work to document the synergistic effect of adding
palliative care to the clinical care of patients with advanced
heart failure is needed. Our understanding of health-related
quality of life—“the functional effect of an illness and its
consequent therapy on a patient, as perceived by the pa-
tient”38—for patients with advanced heart disease is limited
as well.202 Although health-related quality-of-life measure-
ments have been developed for patients with symptomatic
heart failure,203,204 questions remain about their sensitivity in
very advanced stages of disease. There has been some interest
in developing self-report instruments to assess quality of life
at the end of life, but they have not been thoroughly tested
and validated.205 Primarily, there has been relatively slow
uptake of health-related quality-of-life instruments in the
evaluation of therapies and in the routine care of patients. Our
understanding of the burden and quality of life of caregivers
of heart failure patients is even more limited, as is knowledge
about how best to intervene to maximize caregiver quality of
life.
Conclusions
The importance of shared decision making in advanced
heart failure cannot be overstated given the complex
myriad of treatment options that confront patients, fami-
lies, and caregivers. We have offered a roadmap for when
and how to have conversations with patients to support
shared decision making. This process must occur in the
context of uncertainties in prognosis, multiple and often
competing outcomes, and barriers to communication. Al-
though the promotion of shared decision making may seem
daunting to busy practicing clinicians, we have attempted
to provide guiding principles and simple tools that can help
set future expectations, anticipate major decisions, and
promote productive conversations. Our statement is a “call
to action,” not only to clinicians within our community
directly responsible for facilitating shared decision making
but also to those on a national level who would reform and
restructure the healthcare medical system to truly support
patient-centered care.
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